Arcutis Biotherapeutics Inc (ARQT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Arcutis Biotherapeutics Inc (ARQT) has a cash flow conversion efficiency ratio of 0.057x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($12.64 Million) by net assets ($220.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Arcutis Biotherapeutics Inc worth for the company's overall valuation and market capitalisation.
Arcutis Biotherapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Arcutis Biotherapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Arcutis Biotherapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arcutis Biotherapeutics Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of Arcutis Biotherapeutics Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jumbo S.A.
AT:BELA
|
0.023x |
|
California Water Service Group
NYSE:CWT
|
0.035x |
|
Becle S.A.B. de C.V
MX:CUERVO
|
0.026x |
|
Kemira Oyj
HE:KEMIRA
|
0.075x |
|
OLAM GROUP LTD
F:K25
|
N/A |
|
Azelis Group NV
BR:AZE
|
0.020x |
|
Agilysys Inc
NASDAQ:AGYS
|
0.023x |
|
BBVA Banco Frances SA ADR
NYSE:BBAR
|
0.420x |
Annual Cash Flow Conversion Efficiency for Arcutis Biotherapeutics Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Arcutis Biotherapeutics Inc from 2017 to 2025. View Arcutis Biotherapeutics Inc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $189.48 Million | $-5.62 Million | -0.030x | +95.83% |
| 2024-12-31 | $157.54 Million | $-112.16 Million | -0.712x | +74.45% |
| 2023-12-31 | $88.67 Million | $-247.06 Million | -2.786x | -126.59% |
| 2022-12-31 | $209.58 Million | $-257.71 Million | -1.230x | -109.61% |
| 2021-12-31 | $297.68 Million | $-174.63 Million | -0.587x | -40.45% |
| 2020-12-31 | $270.62 Million | $-113.03 Million | -0.418x | +1.07% |
| 2019-12-31 | $101.46 Million | $-42.84 Million | -0.422x | -171.90% |
| 2018-12-31 | $-23.99 Million | $-14.09 Million | 0.587x | -22.33% |
| 2017-12-31 | $-4.99 Million | $-3.77 Million | 0.756x | -- |
About Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a po… Read more